SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is caught in a broad semiconductor selloff as traders worry that election results and growing opposition to data-center projects could slow AI infrastructure spending. The community is split between viewing the drop as an overreaction and buying opportunity and warning that slower buildouts could undermine growth expectations for the AI trade.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

A sharp broad-market selloff following the midterm rally has pressured DIA, as traders debate whether Democratic control and resistance to data-center projects could slow AI spending and spread tech weakness across the market. The discussion is mostly bearish and wary of further volatility, though some see the Dows relative resilience and rotation away from tech as a buying opportunity.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

MAGS is under pressure amid concerns that Big Techs heavy AI and data-center spending is weighing on cash flow and may not earn adequate returns, alongside weakness in mega-cap technology shares. Bears see further downside and question the AI trade, while some traders view the pullback as a buying opportunity or expect support to hold.

Teradyne, Inc.. The Group's principal activity is to design, manufacture, sell and service automatic test equipment for electronic companies. It operates in two segments: Semiconductor Test Systems and System Test Group. Semiconductor Test Systems segment designs, manufactures, sells and supports Semiconductor Test products and services on a world wide basis. Systems Test Group segment is comprised of 3 business units: Mil/Aero, Commercial Board Test and Diagnostic Solutions. It also operates in the Semiconductor Test; Military/Aerospace test, Commercial Circuit Board test and Automotive Diagnostics test. On 14-Nov-2008, it acquired Eagle Test Systems Inc, On 24-Jan-2008, it acquired Nextest Systems Corporation ('Nextest').

Teradyne, Inc.

Teradynes sharp selloff despite a strong Q3 beat is fueling debate over its outlook: traders cite cautious near-term guidance, margin pressure and a high valuation, while others see the drop as an oversold buying opportunity given AI-chip testing demand. Broader weakness in AI and semiconductor stocks is adding pressure.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sareptas quarterly update showed strength in its PMO franchise and a higher revenue outlook, but ELEVIDYS sales remained flat, drawing criticism and contributing to a negative reaction. Traders are also focused on upcoming DM1 and FSHD readouts, with optimism about the pipeline tempered by uncertainty over the results.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCrysts quarterly results beat expectations and raised total revenue guidance, but ORLADEYOs outlook was unchanged and its sales included a pharmacy inventory build, tempering enthusiasm about underlying growth. Traders also point to broader market and biotech weakness, while debate continues over whether ORLADEYO cash flow can offset debt and uncertainty around the Navenibart pipeline.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp broad-market selloff, led by technology and AI-related shares, has traders focused on whether political pushback could slow data-center expansion and AI infrastructure spending. The community is split between calling the decline an overreaction and buying the dip, and warning that an AI-trade unwind and forced selling could prolong the correction.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings Q3 results missed expectations and its reduced FY2026 outlook sparked a sharp selloff. Traders are debating whether heavy investment in its Predictions business and competition from Kalshi and Polymarket can pay off, with frustrated bears criticizing costs and management while some buyers see long-term growth potential.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Rigels quarterly results sparked a sharp selloff, with traders focused on weaker-than-hoped earnings and margins despite record product sales. The community is split between concern over the results and optimism about VEPPANUs early launch uptake, while upcoming R289 data is another focus.

X-Energy, Inc. engages in the development of advanced small modular nuclear reactors and fuel technology for clean energy generation. Its solutions include Xe-100 and TRISO-X. The company was founded by Kam Ghaffarian and Eben Mulder in 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-Energy Inc

XE is drawing attention amid a sharp selloff, which traders attribute to broad weakness in nuclear stocks and bearish analyst coverage; some also blame post-IPO share-sale pressure. The community is split between buying the dip on X-energys Amazon backing and long-term demand for nuclear power, and cautioning that projects and commercialization remain years away.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$BB Sitting, waiting, wishing it was 2031 and I could retire from selling some BB

Motts

Ronghu1399@gmail.com

StockTwits for iOS

BlackBerry Ltd

 Sitting, waiting, wishing it was 2031 and I could retire from selling some BB